Search

Your search keyword '"Qiu, Xiao-Long"' showing total 173 results
Start Over Author "Qiu, Xiao-Long"
173 results on '"Qiu, Xiao-Long"'

3. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors

Author

Zhu, Jiewen, Chen, Hongyuan, Guo, Xuning Emily, Qiu, Xiao-Long, Hu, Chun-Mei, Chamberlin, A Richard, and Lee, Wen-Hwa

Subjects
Cancer, Breast Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Antineoplastic Agents, Benzyl Compounds, Cell Line, Tumor, Cell Proliferation, Dose-Response Relationship, Drug, Drug Design, Drug Screening Assays, Antitumor, Humans, Models, Molecular, Molecular Structure, Rad51 Recombinase, Structure-Activity Relationship, Thiazoles, RAD51 inhibitor, lndole alkaloid, Breast cancer, Triple-negative, QSAR, Synthesis, Indole alkaloid, Medicinal and Biomolecular Chemistry, Organic Chemistry, Pharmacology and Pharmaceutical Sciences, Medicinal & Biomolecular Chemistry
Abstract

RAD51 recombinase plays a critical role for cancer cell proliferation and survival. Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple negative breast cancers which are often resistant to existing therapeutics. To this end, we have designed, synthesized and evaluated a panel of new RAD51 inhibitors, denoted IBR compounds. Among these compounds, we have identified a novel small molecule RAD51 inhibitor, IBR120, which exhibited a 4.8-fold improved growth inhibition activity in triple negative human breast cancer cell line MBA-MD-468. IBR120 also inhibited the proliferation of a broad spectrum of other cancer cell types. Approximately 10-fold difference between the IC50 values in normal and cancer cells were observed. Moreover, IBR120 was capable of disrupting RAD51 multimerization, impairing homologous recombination repair, and inducing apoptotic cell death. Therefore, these novel RAD51 inhibitors may serve as potential candidates for the development of pharmaceutical strategies against difficult-to-treat cancers.

Published
2015

4. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia

Author

Zhu, Jiewen, Zhou, Longen, Wu, Guikai, Konig, Heiko, Lin, Xiaoqin, Li, Guideng, Qiu, Xiao-Long, Chen, Chi-Fen, Hu, Chun-Mei, Goldblatt, Erin, Bhatia, Ravi, Chamberlin, A. Richard, Chen, Phang-Lang, and Lee, Wen-Hwa

Subjects
Cancer, Cml, Inhibitor, Rad51, Small MoleculeDna-Damage Response, Homologous Recombination, Synaptonemal Complexes, Mammalian-Cells, Tumor-Cells, Brc Repeats, Bcr-Abl, Protein, Radiation, Repair
Published
2013

18. Practical Synthesis of Pimobendan

Author

Qiu, Xiao-Long, primary, Gou, Shao-Hua, primary, Wei, Wanguo, additional, Zou, Ping, additional, Hu, Lin, additional, Yan, Xi-Meng, additional, and Li, Xiao-Yue, additional

Published
2019
Full Text
View/download PDF

19. Association between genetic polymorphism of heme oxygenase 1 promoter and neonatal hyperbilirubinemia: a meta-analysis.

Author

Zhou, Jin-Fu, Luo, Jin-Ying, Zhu, Wen-bin, Yang, Chang-Yi, Zeng, Ying-Lin, and Qiu, Xiao-Long

Subjects
NEONATAL jaundice, GENETIC polymorphisms, HEME oxygenase, PROMOTERS (Genetics), GENETIC models, CYTOTOXIC T lymphocyte-associated molecule-4, RESEARCH, FERRANS & Powers Quality of Life Index, META-analysis, OXYGENASES, RESEARCH methodology, ARTHRITIS Impact Measurement Scales, EVALUATION research, COMPARATIVE studies, DISEASE susceptibility, GENOTYPES, GENES
Abstract

Objective: The association between a (GT)n dinucleotide length polymorphism in the promoter region of heme oxygenase 1 (HMOX1) and the risk of neonatal hyperbilirubinemia remains controversial. This meta-analysis was, therefore, performed with aims to examine the correlation between the HMOX1 (GT)n repeat length polymorphism and neonatal hyperbilirubinemia susceptibility.Materials and methods: We searched the databases including PubMed, Embase, Cochrane Library, China national knowledge infrastructure (CNKI), and Wanfang Data, with all reviewed studies published before 28 June 2018. After the evaluation of quality, we used RevMan to perform the meta-analyses. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the effect of HMOX1 gene promoter polymorphisms on the risk of neonatal hyperbilirubinemia.Results: Seven studies, involving 584 patients with neonatal hyperbilirubinemia and 1655 controls, were included. A statistically significant association was found between the HMOX1 (GT)n repeat length polymorphism and risk of neonatal hyperbilirubinemia under the allele (allele S vs. allele L: OR = 1.81, 95% CI = 1.22-2.67, p = .003), recessive (genotype SS vs. genotypes LS + LL: OR = 1.38, 95% CI = 1.02-1.86, p = .04), dominant (genotypes SS + LS vs. LL: OR = 1.37, 95% CI = 1.01-1.76, p = .01), and homozygous genetic models (genotype SS vs. genotype LL: OR = 1.47, 95% CI = 1.02-2.11, p = .003), but not under the heterozygous genetic model. Interestingly, subgroup analysis revealed that the cutoffs of the S allele < 25 showed significant associations in any of the five genetic models (allele S vs. allele L: OR = 2.26, 95% CI = 1.68-3.05, p < .00001; genotype SS vs. genotypes LS + LL: OR = 2.56, 95% CI = 1.41-4.65, p = .002; genotypes SS + LS vs. genotype LL: OR = 1.82, 95% CI = 1.28-2.59, p = .0009; genotype SS vs. genotype LL: OR = 3.09, 95% CI = 1.50-6.36, p = .002; genotype LS vs. genotype LL: OR = 1.64, 95% CI = 1.11-2.42, p = .01); however, this association was not observed in the cutoffs of the S allele ≥25.Conclusion: The results of this study indicate that there is a significant association between the HMOX1 (GT)n repeat length polymorphism and susceptibility to neonatal hyperbilirubinemia. Newborns carrying shorter (GT)n repeats in the HMOX1 gene promoter may have a higher risk of neonatal hyperbilirubinemia. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results